LitCovid-sentences  

PMC:7283670 / 54646-110173 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T602 0-142 Sentence denotes Study title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date
T603 143-221 Sentence denotes The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug:
T604 222-376 Sentence denotes Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
T605 377-463 Sentence denotes Control group: standard therapy II, III Primary (up to 28 days): all cause mortality
T606 464-763 Sentence denotes Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
T607 764-1116 Sentence denotes Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
T608 1117-1257 Sentence denotes Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days):
T609 1258-1325 Sentence denotes The relief/disappearance rate of main symptoms, chest CT absorption
T610 1326-1438 Sentence denotes Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time.
T611 1439-1562 Sentence denotes The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
T612 1563-1708 Sentence denotes Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020
T613 1709-1816 Sentence denotes Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug:
T614 1817-1939 Sentence denotes Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group:
T615 1940-1995 Sentence denotes 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
T616 1996-2117 Sentence denotes Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
T617 2118-3282 Sentence denotes Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020
T618 3283-3574 Sentence denotes The COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
T619 3575-3850 Sentence denotes Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020
T620 3851-3897 Sentence denotes A Pilot Study of Sildenafil in COVID‐19 Drug:
T621 3898-4190 Sentence denotes Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
T622 4191-4537 Sentence denotes Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020
T623 4538-4737 Sentence denotes Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection
T624 4738-4920 Sentence denotes 30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate:
T625 4921-4947 Sentence denotes 15% − Primary (28 days):
T626 4948-4964 Sentence denotes 28 day mortality
T627 4965-5200 Sentence denotes Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020
T628 5201-5646 Sentence denotes Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4.
T629 5647-5761 Sentence denotes Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4.
T630 5762-5800 Sentence denotes Other: standard public health measures
T631 5801-5991 Sentence denotes Active comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
T632 5992-6400 Sentence denotes Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
T633 6401-6724 Sentence denotes Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
T634 6725-6815 Sentence denotes Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
T635 6816-6947 Sentence denotes No intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
T636 6948-7603 Sentence denotes Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020
T637 7604-8032 Sentence denotes Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
T638 8033-8330 Sentence denotes Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
T639 8331-8516 Sentence denotes Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020
T640 8517-8973 Sentence denotes Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
T641 8974-9165 Sentence denotes Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
T642 9166-9467 Sentence denotes Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020
T643 9468-9646 Sentence denotes Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:
T644 9647-9702 Sentence denotes bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
T645 9703-9909 Sentence denotes No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020
T646 9910-10186 Sentence denotes The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
T647 10187-10247 Sentence denotes Experimental: thalidomide group 100 mg, po, qn, for 14 days.
T648 10248-10369 Sentence denotes Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
T649 10370-10493 Sentence denotes Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
T650 10494-11132 Sentence denotes Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
T651 11133-11569 Sentence denotes The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone:
T652 11570-11603 Sentence denotes 40 mg, q12h, for 5 days. placebo:
T653 11604-11629 Sentence denotes 100 mg/d, qn, for 14 days
T654 11630-11866 Sentence denotes Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone:
T655 11867-11904 Sentence denotes 40 mg, q12h, for 5 days. thalidomide:
T656 11905-11987 Sentence denotes 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement
T657 11988-12735 Sentence denotes Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020
T658 12736-13017 Sentence denotes Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
T659 13018-13242 Sentence denotes No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020
T660 13243-13501 Sentence denotes Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
T661 13502-13660 Sentence denotes No Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020
T662 13661-13987 Sentence denotes Therapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
T663 13988-14262 Sentence denotes Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
T664 14263-14742 Sentence denotes Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
T665 14743-15018 Sentence denotes The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2:
T666 15019-15085 Sentence denotes 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
T667 15086-15256 Sentence denotes Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days):
T668 15257-15325 Sentence denotes Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020
T669 15326-15682 Sentence denotes Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
T670 15683-15851 Sentence denotes WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks):
T671 15852-15893 Sentence denotes Clinical outcome, CT Scan, RT‐PCR results
T672 15894-15971 Sentence denotes Secondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020
T673 15972-16192 Sentence denotes Myocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital
T674 16193-16381 Sentence denotes Dead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
T675 16382-16555 Sentence denotes Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
T676 16556-16987 Sentence denotes Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
T677 16988-17365 Sentence denotes Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
T678 17366-17818 Sentence denotes Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021
T679 17819-18085 Sentence denotes The clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin
T680 18086-18498 Sentence denotes Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
T681 18499-18707 Sentence denotes Efficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
T682 18708-18816 Sentence denotes No intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days
T683 18817-19007 Sentence denotes Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020
T684 19008-19286 Sentence denotes Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names:
T685 19287-19314 Sentence denotes Kevzara®, REGN88, SAR153191
T686 19315-19403 Sentence denotes Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names:
T687 19404-19431 Sentence denotes Kevzara®, REGN88, SAR153191
T688 19432-19728 Sentence denotes Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
T689 19729-21820 Sentence denotes Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
T690 21821-22253 Sentence denotes Washed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
T691 22254-22614 Sentence denotes Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020
T692 22615-23057 Sentence denotes Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
T693 23058-23524 Sentence denotes Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
T694 23525-23857 Sentence denotes Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:
T695 23858-24070 Sentence denotes Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
T696 24071-24081 Sentence denotes Secondary:
T697 24082-24222 Sentence denotes Extubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
T698 24223-24607 Sentence denotes Immunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I
T699 24608-24620 Sentence denotes II Primary:
T700 24621-24759 Sentence denotes Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
T701 24760-24781 Sentence denotes Secondary (0–28 day):
T702 24782-25273 Sentence denotes 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
T703 25274-25519 Sentence denotes Phase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
T704 25520-25551 Sentence denotes Experimental: middle‐dose group
T705 25552-25617 Sentence denotes Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
T706 25618-25647 Sentence denotes Experimental: high‐dose group
T707 25648-25790 Sentence denotes Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions
T708 25791-25842 Sentence denotes Secondary (Day 14, 28, Month 3, 6 postvaccination):
T709 25843-26564 Sentence denotes Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
T710 26565-26609 Sentence denotes Other (day、14,28, Month3,6 postvaccination):
T711 26610-27025 Sentence denotes Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
T712 27026-27338 Sentence denotes Development and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
T713 27339-27455 Sentence denotes We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:
T714 27456-27626 Sentence denotes Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
T715 27627-27863 Sentence denotes Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment
T716 27864-27920 Sentence denotes Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
T717 27921-27948 Sentence denotes Placebo comparator: placebo
T718 27949-28033 Sentence denotes identical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):
T719 28034-28062 Sentence denotes All‐cause hospital mortality
T720 28063-28089 Sentence denotes Secondary (up to120 days):
T721 28090-28250 Sentence denotes Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
T722 28251-28437 Sentence denotes Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental:
T723 28438-28459 Sentence denotes Tocilizumab Injection
T724 28460-28573 Sentence denotes Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):
T725 28574-28598 Sentence denotes One‐month mortality rate
T726 28599-28625 Sentence denotes Secondary (up to 1 month):
T727 28626-29248 Sentence denotes interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization.
T728 29249-29382 Sentence denotes Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
T729 29383-29476 Sentence denotes Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological:
T730 29477-29560 Sentence denotes NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental:
T731 29561-29571 Sentence denotes NestCell®:
T732 29572-29726 Sentence denotes All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):
T733 29727-29777 Sentence denotes Disappear time of ground‐glass shadow in the lungs
T734 29778-29788 Sentence denotes Secondary:
T735 29789-30226 Sentence denotes Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020
T736 30227-30445 Sentence denotes CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment
T737 30446-30543 Sentence denotes Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
T738 30544-30571 Sentence denotes Placebo comparator: placebo
T739 30572-30671 Sentence denotes Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):
T740 30672-30731 Sentence denotes Improvement of COVID‐19 disease status secondary (14 days):
T741 30732-31081 Sentence denotes Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022
T742 31082-31262 Sentence denotes Acute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:
T743 31263-31305 Sentence denotes COVID‐19 patients with acute kidney injury
T744 31306-31329 Sentence denotes nonacute kidney injury:
T745 31330-31378 Sentence denotes COVID‐19 patients without acute kidney injury –
T746 31379-31447 Sentence denotes Rate of death, the length of hospital stay Primary (up to 60 days):
T747 31448-31475 Sentence denotes Rate of acute kidney injury
T748 31476-31543 Sentence denotes Secondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020
T749 31544-31724 Sentence denotes Phase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)
T750 31725-31753 Sentence denotes Experimental: low‐dose group
T751 31754-31819 Sentence denotes Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
T752 31820-31851 Sentence denotes Experimental: middle‐dose group
T753 31852-31917 Sentence denotes Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
T754 31918-32054 Sentence denotes Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):
T755 32055-32090 Sentence denotes Safety indexes of adverse reactions
T756 32091-32162 Sentence denotes Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
T757 32163-33053 Sentence denotes Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
T758 33054-33097 Sentence denotes Other (Day 14,28, Month 6 postvaccination):
T759 33098-33753 Sentence denotes Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
T760 33754-34024 Sentence denotes Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group
T761 34025-34037 Sentence denotes Favipiravir:
T762 34038-34146 Sentence denotes On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day.
T763 34147-34225 Sentence denotes Oral administration, the maximum number of days taken is not more than 7 days.
T764 34226-34302 Sentence denotes Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg.
T765 34303-34490 Sentence denotes For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr.
T766 34491-34512 Sentence denotes Intravenous infusion.
T767 34513-34604 Sentence denotes The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
T768 34605-34641 Sentence denotes Active comparator: favipiravir group
T769 34642-34750 Sentence denotes On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day.
T770 34751-34828 Sentence denotes Oral administration, the maximum number of days taken is not more than 7 days
T771 34829-34865 Sentence denotes Active comparator: tocilizumab group
T772 34866-34929 Sentence denotes The first dose is 4–8 mg/kg and the recommended dose is 400 mg.
T773 34930-35117 Sentence denotes For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr.
T774 35118-35268 Sentence denotes Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):
T775 35269-35287 Sentence denotes Clinical cure rate
T776 35288-35330 Sentence denotes Secondary (14 days after taking medicine):
T777 35331-35700 Sentence denotes Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020
T778 35701-35921 Sentence denotes Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1.
T779 35922-36018 Sentence denotes 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):
T780 36019-36068 Sentence denotes Disppear time of ground‐glass shadow in the lungs
T781 36069-36079 Sentence denotes Secondary:
T782 36080-36258 Sentence denotes Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
T783 36259-36611 Sentence denotes Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:
T784 36612-36788 Sentence denotes Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
T785 36789-36843 Sentence denotes Active comparator: control group of ordinary COVID‐19:
T786 36844-36942 Sentence denotes Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
T787 36943-36995 Sentence denotes Experimental: experimental group of severe COVID‐19:
T788 36996-37197 Sentence denotes Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:
T789 37198-37290 Sentence denotes Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
T790 37291-37462 Sentence denotes Prognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):
T791 37463-37482 Sentence denotes all‐cause mortality
T792 37483-37503 Sentence denotes Secondary (15 days):
T793 37504-37524 Sentence denotes all‐cause mortality,
T794 37525-37576 Sentence denotes Severe state NCT04292964/Completed Mar1‐Mar13 2020
T795 37577-37815 Sentence denotes Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:
T796 37816-37935 Sentence denotes a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
T797 37936-38014 Sentence denotes Placebo comparator: placebo Not applicable Primary (approximately 100 days):
T798 38015-38056 Sentence denotes Number of symptomatic COVID‐19 infections
T799 38057-38092 Sentence denotes Secondary (approximately 100 days):
T800 38093-38361 Sentence denotes Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
T801 38362-38393 Sentence denotes Other (approximately 100 days):
T802 38394-38482 Sentence denotes Drug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022
T803 38483-38555 Sentence denotes Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug:
T804 38556-38586 Sentence denotes YinHu QingWen decoction, drug:
T805 38587-38628 Sentence denotes YinHu QingWen decoction(low dose), other:
T806 38629-38788 Sentence denotes Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental:
T807 38789-38820 Sentence denotes Yin Hu Qing Wen decoction group
T808 38821-38944 Sentence denotes Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
T809 38945-38950 Sentence denotes Drug:
T810 38951-39132 Sentence denotes YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth.
T811 39133-39241 Sentence denotes The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
T812 39242-39308 Sentence denotes It will be given a 200 ml per time, three times a day, for 10 days
T813 39309-39495 Sentence denotes Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
T814 39496-39515 Sentence denotes Placebo comparator:
T815 39516-39554 Sentence denotes Yinhu Qingwen decoction low‐dose group
T816 39555-39689 Sentence denotes Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
T817 39690-39695 Sentence denotes Drug:
T818 39696-39807 Sentence denotes YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula).
T819 39808-39906 Sentence denotes The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
T820 39907-39973 Sentence denotes It will be given a 200 ml per time, three times a day, for 10 days
T821 39974-40186 Sentence denotes Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
T822 40187-40251 Sentence denotes Active comparator: integrated Chinese and western medicine group
T823 40252-40391 Sentence denotes Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms.
T824 40392-40536 Sentence denotes The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml).
T825 40537-40628 Sentence denotes The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
T826 40629-40635 Sentence denotes Other:
T827 40636-40662 Sentence denotes Chinese medicine treatment
T828 40663-40800 Sentence denotes This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
T829 40801-40843 Sentence denotes Other: standard western medicine treatment
T830 40844-41017 Sentence denotes Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II
T831 41018-41047 Sentence denotes III Primary (up to 28 days):
T832 41048-41075 Sentence denotes Mean clinical recovery time
T833 41076-41102 Sentence denotes Secondary (up to 28 days):
T834 41103-41610 Sentence denotes Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
T835 41611-41910 Sentence denotes Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
T836 41911-42044 Sentence denotes Prognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment
T837 42045-42142 Sentence denotes hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
T838 42143-42150 Sentence denotes Control
T839 42151-42280 Sentence denotes hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):
T840 42281-42353 Sentence denotes Occupancy rate in the intensive care unit, mechanical ventilation, death
T841 42354-42380 Sentence denotes Secondary (up to 28 days):
T842 42381-42532 Sentence denotes All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020
T843 42533-42994 Sentence denotes Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:
T844 42995-43060 Sentence denotes Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
T845 43061-43185 Sentence denotes Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection.
T846 43186-43255 Sentence denotes Arbidol hydrochloride granules is recommended but not enforced to use
T847 43256-43295 Sentence denotes Recombinant human interferon α2b spray:
T848 43296-43419 Sentence denotes Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
T849 43420-43439 Sentence denotes Favipiravir tablets
T850 43440-43481 Sentence denotes Active comparator; group B control group:
T851 43482-43518 Sentence denotes Drug: arbidol hydrochloride granules
T852 43519-43713 Sentence denotes Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
T853 43714-43758 Sentence denotes Drug: recombinant human interferon α2b spray
T854 43759-43954 Sentence denotes Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):
T855 43955-43996 Sentence denotes Time to clinical recovery after treatment
T856 43997-44053 Sentence denotes Secondary (within 14 days from the start of medication):
T857 44054-44603 Sentence denotes Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
T858 44604-44882 Sentence denotes Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19
T859 44883-44958 Sentence denotes Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
T860 44959-45013 Sentence denotes Experimental: lopinavir and ritonavir plus favipiravir
T861 45014-45190 Sentence denotes Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
T862 45191-45261 Sentence denotes Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
T863 45262-45349 Sentence denotes Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
T864 45350-45426 Sentence denotes Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
T865 45427-45536 Sentence denotes Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
T866 45537-45591 Sentence denotes Experimental: favipiravir lopinavir/ritonavir for mod.
T867 45592-45601 Sentence denotes To severe
T868 45602-45802 Sentence denotes favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
T869 45803-45871 Sentence denotes Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
T870 45872-46041 Sentence denotes Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
T871 46042-46110 Sentence denotes Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
T872 46111-46356 Sentence denotes Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
T873 46357-46396 Sentence denotes No intervention: conventional qurantine
T874 46397-46505 Sentence denotes Patient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):
T875 46506-46533 Sentence denotes SARS‐CoV‐2 eradication time
T876 46534-46561 Sentence denotes Secondary (up to 24 weeks):
T877 46562-46826 Sentence denotes Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
T878 46827-46850 Sentence denotes Other (up to 24 weeks):
T879 46851-46968 Sentence denotes Number of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
T880 46969-47034 Sentence denotes Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug:
T881 47035-47063 Sentence denotes Yinhu Qingwen granula, drug:
T882 47064-47240 Sentence denotes Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:
T883 47241-47269 Sentence denotes Yinhu Qingwen granula group:
T884 47270-47275 Sentence denotes Drug:
T885 47276-47297 Sentence denotes Yinhu Qingwen Granula
T886 47298-47505 Sentence denotes Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc.
T887 47506-47604 Sentence denotes The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
T888 47605-47672 Sentence denotes It will be given a 200 ml per time, three times a day, for 10 days.
T889 47673-47877 Sentence denotes Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
T890 47878-47897 Sentence denotes Placebo comparator:
T891 47898-47935 Sentence denotes Yinhu Qingwen granula low‐dose group:
T892 47936-47941 Sentence denotes Drug:
T893 47942-47977 Sentence denotes Yin Hu Qing Wen granula (low does).
T894 47978-48140 Sentence denotes This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
T895 48141-48345 Sentence denotes Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
T896 48347-48368 Sentence denotes II Primary (Day 10):
T897 48369-48419 Sentence denotes changes in the ratio of PaO2 to FiO2 from baseline
T898 48420-48446 Sentence denotes Secondary (up to 30 days):
T899 48447-49223 Sentence denotes PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
T900 49224-49392 Sentence denotes Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group
T901 49393-49542 Sentence denotes Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
T902 49543-49764 Sentence denotes Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):
T903 49765-49871 Sentence denotes The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
T904 49872-49892 Sentence denotes Secondary (2 weeks):
T905 49893-50352 Sentence denotes Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
T906 50353-50557 Sentence denotes The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental:
T907 50558-50937 Sentence denotes The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
T908 50938-50978 Sentence denotes No intervention: the blank control group
T909 50979-51173 Sentence denotes All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
T910 51175-51349 Sentence denotes Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
T911 51350-51375 Sentence denotes Secondary (Day −1 to 10):
T912 51376-52560 Sentence denotes The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
T913 52561-52657 Sentence denotes Immunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug:
T914 52658-52799 Sentence denotes Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group
T915 52800-52840 Sentence denotes Anti‐PD‐1 antibody, 200 mg, IV, one time
T916 52841-52869 Sentence denotes Experimental: thymosin group
T917 52870-52909 Sentence denotes Thymosin, 1.6 mg sc qd, last for 5 days
T918 52910-52982 Sentence denotes Placebo comparator: control group stand treatment II Primary (7 days):
T919 52983-53000 Sentence denotes lung injury score
T920 53001-53011 Sentence denotes Secondary:
T921 53012-53282 Sentence denotes Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
T922 53283-53552 Sentence denotes Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab
T923 53553-53690 Sentence denotes Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min.
T924 53691-53766 Sentence denotes Tocilizumab was administered according—continuous renal replacement therapy
T925 53767-53914 Sentence denotes Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
T926 53915-53928 Sentence denotes Standard care
T927 53929-54023 Sentence denotes Standard of care therapy per local written policies or guidelines – Primary (up to 14 days):
T928 54024-54100 Sentence denotes Proportion of participants with normalization of fever and oxygen saturation
T929 54101-54111 Sentence denotes Secondary:
T930 54112-54691 Sentence denotes Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020
T931 54692-54955 Sentence denotes Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver
T932 54956-55029 Sentence denotes caregivers from emergency, ICU, virology and infectious disease services:
T933 55030-55103 Sentence denotes Two blood samples at T0 and 3 months Not applicable Primary (3 months):
T934 55104-55211 Sentence denotes Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
T935 55212-55233 Sentence denotes Secondary (3 months):
T936 55234-55527 Sentence denotes Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020